ARTICLE | Politics, Policy & Law

BIO still mulling orphan drug compromise

June 28, 1993 7:00 AM UTC

BIO still mulling orphan drug compromise The Biotechnology Industry Organization hopes to discuss its proposed Orphan Drug Act compromise bill at the next executive board meeting at the end of the month, according to spokesperson Eric Christiansen.

According to a draft of the proposal, which was circulated last month to directors of the BIO's precursor organizations, the compromise would reduce market exclusivity for orphan drugs to five years in exchange for termination of efforts by lawmakers to put caps on orphan revenues. It also provided for four years of market exclusivity for all drugs approved under a specific definition of "biotechnology drugs," regardless of the size of the patient population...